Equities Analysts Issue Forecasts for LENZ Q1 Earnings

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Stock analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for LENZ Therapeutics in a report released on Wednesday, March 19th. Leerink Partnrs analyst M. Goodman forecasts that the company will post earnings per share of ($0.53) for the quarter. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share. Leerink Partnrs also issued estimates for LENZ Therapeutics’ Q2 2025 earnings at ($0.62) EPS and Q4 2025 earnings at ($0.83) EPS.

LENZ has been the subject of several other reports. TD Cowen began coverage on shares of LENZ Therapeutics in a report on Tuesday, March 18th. They issued a “buy” rating and a $60.00 target price for the company. Citigroup upped their price target on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, March 20th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, LENZ Therapeutics presently has a consensus rating of “Buy” and an average price target of $41.67.

LENZ Therapeutics Stock Up 0.6 %

Shares of LENZ opened at $26.66 on Monday. LENZ Therapeutics has a 52 week low of $14.42 and a 52 week high of $38.93. The stock has a market cap of $733.18 million, a price-to-earnings ratio of -5.59 and a beta of 0.58. The business has a 50-day simple moving average of $24.22 and a two-hundred day simple moving average of $27.10.

LENZ Therapeutics (NASDAQ:LENZ) last announced its earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of LENZ Therapeutics during the fourth quarter valued at approximately $29,000. SG Americas Securities LLC grew its stake in LENZ Therapeutics by 20.7% during the fourth quarter. SG Americas Securities LLC now owns 5,458 shares of the company’s stock valued at $158,000 after acquiring an additional 935 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in LENZ Therapeutics by 14.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,914 shares of the company’s stock valued at $229,000 after acquiring an additional 1,005 shares during the last quarter. Rhumbline Advisers lifted its stake in LENZ Therapeutics by 6.2% in the 4th quarter. Rhumbline Advisers now owns 18,754 shares of the company’s stock worth $541,000 after purchasing an additional 1,100 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of LENZ Therapeutics by 162.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company’s stock valued at $54,000 after purchasing an additional 1,151 shares during the last quarter. 54.32% of the stock is currently owned by institutional investors.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.